Cystic fibrosis in the crosshairs as Carbon Biosciences launches with $38M
Carbon Biosciences, a biotech company developing parvovirus-derived gene therapies, has launched with $38M of financing led by Agent Capital.
Johnf Engelhardt Robertm Kotin Geeta Vemuri Joel Schneider Astellas Venture Management University Of Iowa
Source: labiotech.eu